uniQure (NASDAQ:QURE) Stock Crosses Above 50-Day Moving Average - What's Next?

Key Points

• uniQure N.V. (NASDAQ:QURE) shares have recently crossed above their 50-day moving average of $14.91, trading as high as $15.48 before closing at $15.21.
• Despite an upgrade from some analysts, the stock currently holds a Moderate Buy rating with an average target price of $37.82, alongside recent downgrades from certain firms.
• Insider trading activity has been noted, with directors selling shares and a total of 22,144 shares sold by insiders over the past 90 days.

uniQure N.V. (NASDAQ:QURE - Get Free Report) shares passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $14.91 and traded as high as $15.48. uniQure shares last traded at $15.21, with a volume of 824,768 shares trading hands.

Analysts Set New Price Targets

Several research firms have weighed in on QURE. Chardan Capital reissued a "buy" rating and set a $38.00 price target on shares of uniQure in a research report on Friday, May 30th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of uniQure in a research note on Thursday, May 29th. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Finally, Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, uniQure has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Trading Down 0.7%

The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. The stock has a market cap of $827.73 million, a price-to-earnings ratio of -3.44 and a beta of 0.08. The company's fifty day moving average price is $14.94 and its 200-day moving average price is $13.68.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. The business had revenue of $1.57 million during the quarter, compared to analyst estimates of $5.93 million. On average, research analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling at uniQure

In other uniQure news, Director Rachelle Suzanne Jacques sold 2,112 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director owned 28,346 shares in the company, valued at $409,599.70. The trade was a 6.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Madhavan Balachandran sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director directly owned 37,697 shares of the company's stock, valued at approximately $544,721.65. This trade represents a 5.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,144 shares of company stock worth $322,426. Insiders own 4.79% of the company's stock.

Institutional Investors Weigh In On uniQure

A number of institutional investors have recently made changes to their positions in QURE. Invesco Ltd. raised its stake in uniQure by 453.2% during the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after buying an additional 502,684 shares during the period. Assenagon Asset Management S.A. raised its position in uniQure by 355.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock worth $3,550,000 after purchasing an additional 261,323 shares during the period. Raymond James Financial Inc. purchased a new position in shares of uniQure during the fourth quarter valued at about $1,951,000. Northern Trust Corp boosted its stake in uniQure by 2.1% during the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock worth $1,688,000 after acquiring an additional 1,923 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of uniQure by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock valued at $9,198,000 after purchasing an additional 11,951 shares during the last quarter. Institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.